

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
15 September 2022 (15.09.2022)



(10) International Publication Number
WO 2022/187968 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 37/06 (2006.01)
A61K 39/395 (2006.01) C12N 15/13 (2006.01)
A61P 35/00 (2006.01) C12P 21/08 (2006.01)
A61P 37/02 (2006.01)

(21) International Application Number:

PCT/CA2022/050363

(22) International Filing Date:

11 March 2022 (11.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/159,613 11 March 2021 (11.03.2021) US

(71) Applicant: UNIVERSITY HEALTH NETWORK

[CA/CA]; 190 Elizabeth Street, R. Fraser Elliot Building -
Room 1S-417, Toronto, Ontario M5G 2C4 (CA).

(72) Inventors: BROKX, Richard; c/o University Health Net-

work, 190 Elizabeth Street, R. Fraser Elliot Building -
Room 1S-417, Toronto, Ontario M5G 2C4 (CA). MASON,
Jacqueline M.; c/o University Health Network, 190 Eliza-
beth Street, R. Fraser Elliot Building -Room 1S-417, Toron-
to, Ontario M5G 2C4 (CA). BRAY, Mark Robert; c/o Uni-

versity Health Network, 190 Elizabeth Street, R. Fraser El-
liot Building - Room 1S-417, Toronto, Ontario M5G 2C4
(CA). DUNCAN, Gordon S.; c/o University Health Net-
work, 190 Elizabeth Street, R. Fraser Elliot Building - Room
1S-417, Toronto, Ontario M5G 2C4 (CA).

(74) Agent: BOWN, Christopher et al.; GOWLING WLG

(CANADA) LLP, Suite 2600, 160 Elgin Street, Ottawa, On-
tario K1P 1C3 (CA).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.


(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: LILRB1 AND LILRB2-BINDING MOLECULES AND USES THEREFOR

FIG. 2A

HLA-G-PE Tetramer Binding to Primary Classical Monocytes



(57) Abstract: The invention provides novel anti-LILR antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer, autoimmune disease, or allergic inflammation.

[Continued on next page]

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*